Novavax
NVAX
$4.09
Share price
3.54%
Change (1 day)
-46.68%
Change (1 year)
Categories
Novavax (NVAX) - Cash on Hand
Cash on Hand as of December 2023 : $0.56 B
According to Novavax's latest financial reports the company has $0.56 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Novavax - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.56 B | -57.48% |
| 2022-12-31 | $1.33 B | -11.76% |
| 2021-12-31 | $1.51 B | 113.08% |
| 2020-12-31 | $0.71 B | 802.08% |
| 2019-12-31 | $78.82 M | -14.45% |
| 2018-12-31 | $92.13 M | -41.43% |
| 2017-12-31 | $0.15 B | -33.2% |
| 2016-12-31 | $0.23 B | 2.09% |
| 2015-12-31 | $0.23 B | 37.25% |
| 2014-12-31 | $0.16 B | 26.29% |
| 2013-12-31 | $0.13 B | 201.67% |
| 2012-12-31 | $44.11 M | 140.93% |
| 2011-12-31 | $18.3 M | -42.2% |
| 2010-12-31 | $31.67 M | -26.25% |
| 2009-12-31 | $42.95 M | 26.7% |
| 2008-12-31 | $33.9 M | -27.08% |
| 2007-12-31 | $46.48 M | -36.83% |
| 2006-12-31 | $73.59 M | 130.76% |
| 2005-12-31 | $31.89 M | 78.41% |
| 2004-12-31 | $17.87 M | -35.31% |
| 2003-12-31 | $27.63 M | 819.57% |
| 2002-12-31 | $3 M | -85.01% |
| 2001-12-31 | $20.04 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $9.69 B | 1,605.17% | 🇨🇭 Switzerland |
 Pfizer PFE | $12.69 B | 2,132.17% | 🇺🇸 USA |
 AstraZeneca AZN | $8.02 B | 1,310.89% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $6.35 B | 1,017.81% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | $1.67 B | 194.85% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $0.42 B | -25.49% | 🇺🇸 USA |
 Agenus
AGEN | $76.11 M | -86.61% | 🇺🇸 USA |
 NanoViricides NNVC | $5.24 M | -99.08% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | $0.38 B | -31.58% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | $0.11 B | -80.35% | 🇺🇸 USA |